---
schema_version: "secwatch.filing_event.v1"
accession: "0000885725-23-000041"
form_type: "8-K"
ticker: "BSX"
cik: "0000885725"
company_name: "BOSTON SCIENTIFIC CORP"
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T01:49:37.184469+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Boston Scientific Q2 beats: $3.599B revenue (+11% reported), adj. EPS $0.53 vs guidance $0.48-$0.50

## Summary
- Revenue $3.599B, +11% reported, +11.6% organic; beat guidance of 6.5-8.5% reported.
- GAAP EPS $0.18 (GAAP net income $261M); adjusted EPS $0.53 vs guidance $0.48-$0.50.
- Cardiovascular segment grew 12.2% reported; MedSurg grew 9.0% reported.
- Full-year 2023 guidance raised: reported revenue growth ~10.5-11.5%, adj. EPS $1.96-$2.00.
- Q3 guidance: reported revenue growth 8.5-10.5%, adj. EPS $0.46-$0.48.

## SEC filing metadata
- accession: 0000885725-23-000041
- form_type: 8-K
- ticker: BSX
- cik: 0000885725
- company_name: BOSTON SCIENTIFIC CORP
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/0000885725-23-000041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/bsx-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000885725-23-000041
- JSON: https://secwatch.observer/filing/0000885725-23-000041.json
- Plain text: https://secwatch.observer/filing/0000885725-23-000041.txt

## Key facts
- Earnings Releases
  BOSTON SCIENTIFIC CORP reported the second quarter ended June 30, 2023 results: revenue $3.599 billion, net income $261 million, EPS $0.18 per share (EPS).
  - Period: the second quarter ended June 30, 2023
  - Revenue: $3.599 billion
  - Net income: $261 million
  - EPS: $0.18 per share (EPS)
  - Result: reported results
  source text: Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.599 billion during the second quarter of 2023, growing 11.0 percent on a reported basis, 12.0 percent on an operational 1 basis and 11.6 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $261 million or $0.18 per share (EPS), compared to $246 million or $0.17 per share a year ago, and achieved adjusted 3 EPS of $0.53 for the period, compared to $0.44 a year ago.
  evidence_url: https://www.sec.gov/Archives/edgar/data/885725/000088572523000041/0000885725-23-000041-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.